Steven Cohen Kymera Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$13.9 - $23.88 $1.13 Million - $1.94 Million	81,400 New	81,400 $1.13 Million
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $9.22 Million - $27.8 Million	-652,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $21 Million - $38.5 Million	594,600 Added 1021.65%	652,800 $27.6 Million
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $4.95 Million - $6.5 Million	-99,200 Reduced 63.02%	58,200 $3.7 Million
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $4.29 Million - $5.99 Million	89,800 Added 132.84%	157,400 $9.25 Million
Q2 2021 Aug 16, 2021	BUY	$31.08 - $51.95 $2.1 Million - $3.51 Million	67,600 New	67,600 $3.28 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.